1
|
Long F, Chen S, Li R, Lin Y, Han J, Guo J, Chen Y, Li C, Song P. Efficacy and safety of HAIC alone vs. HAIC combined with lenvatinib for treatment of advanced hepatocellular carcinoma. Med Oncol 2023; 40:147. [PMID: 37043113 DOI: 10.1007/s12032-023-02012-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2023] [Accepted: 03/24/2023] [Indexed: 04/13/2023]
Abstract
To investigate efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib (HAIC-Len) and HAIC alone for the treatment of advanced hepatocellular carcinoma (Ad-HCC). Totally 349 patients with Ad-HCC participated in the research from February 2018 to October 2020. On the basis of propensity score matching (PSM), 132 and 110 cases were assigned to the HAIC group and the HAIC-Len group, respectively, with a ratio of 1:1. Progression-free survival (PFS), overall survival (OS), and complications were compared between two groups. The Kaplan-Meier method and log-rank test were utilized to estimate cumulative OS and PFS. Additionally, uni- and multi-variate Cox regression models were employed to identify significant independent factors. The median follow-up period in this study was set to be 20.8 months. Following PSM, the one-, two- and three-year cumulative OS rates in the HAIC-Len and HAIC groups were 63.6%, 12.1%, and 3.0%, and 47.2%, 11.8%, and 2.7%, respectively, with a significant difference (P < 0.001). The first-three-year cumulative incidence rates PFS in the HAIC-Len and the HAIC groups were 15.2%, 1.5%, and ND, and 11.8%, 4.5%, and 3.6%, respectively, with no significant difference detected (P = 0.092). BMI (HR 0.709. 95% CI 0.549, 0.915. P = 0.008) and AST (HR 1.005. 95% CI 1.003, 1.007. P < 0.001) represented independent prognostic factors for OS. Additionally, the two groups exhibited no significant difference in the incidence rates of adverse events. HAIC-Len significantly improved survival outcomes of patients with Ad-HCC and demonstrated acceptable toxicity compared to HAIC alone.
Collapse
Affiliation(s)
- Fang Long
- Department of Gastroenterology, The First Affiliated Hospital of Jinan University, No.613 of West Huangpu Avenue, Guangzhou, 510630, China
| | - Shali Chen
- Department of Cardiology, The First Affiliated Hospital of Jinan University, No. 613 of West Huangpu Avenue, Guangzhou, 510630, China
| | - Ruidong Li
- Department of Interventional Radiology and Vascular Surgery, The First Affiliated Hospital of Jinan University, No. 613 of West Huangpu Avenue, Guangzhou, 510630, China
| | - Yinsheng Lin
- Department of Interventional Radiology and Vascular Surgery, The First Affiliated Hospital of Jinan University, No. 613 of West Huangpu Avenue, Guangzhou, 510630, China
| | - Jian Han
- Department of Interventional Radiology and Vascular Surgery, The First Affiliated Hospital of Jinan University, No. 613 of West Huangpu Avenue, Guangzhou, 510630, China
| | - Jiandong Guo
- Department of Interventional Radiology and Vascular Surgery, The First Affiliated Hospital of Jinan University, No. 613 of West Huangpu Avenue, Guangzhou, 510630, China
| | - Yongxin Chen
- Department of Interventional Radiology and Vascular Surgery, The First Affiliated Hospital of Jinan University, No. 613 of West Huangpu Avenue, Guangzhou, 510630, China
| | - Chengzhi Li
- Department of Interventional Radiology and Vascular Surgery, The First Affiliated Hospital of Jinan University, No. 613 of West Huangpu Avenue, Guangzhou, 510630, China.
| | - Peng Song
- Department of Oncology, The Second Medical Center and National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, 100853, People's Republic of China.
| |
Collapse
|
2
|
Aksoy E, Saveanu L, Manoury B. The Isoform Selective Roles of PI3Ks in Dendritic Cell Biology and Function. Front Immunol 2018; 9:2574. [PMID: 30498491 PMCID: PMC6249308 DOI: 10.3389/fimmu.2018.02574] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2018] [Accepted: 10/18/2018] [Indexed: 11/20/2022] Open
Abstract
Phosphoinositide-3 kinases (PI3Ks) generate 3-phosphorylated phosphoinositide lipids that are implicated in many biological processes in homeostatic states and pathologies such as cancer, inflammation and autoimmunity. Eight isoforms of PI3K exist in mammals and among them the class I PI3K, p110γ, and PI3Kδ, and class III Vps34 being the most expressed and well characterized in immune cells. Following engagement of pathogen recognition receptors (PRRs), PI3Ks coordinate vital cellular processes of signaling and vesicular trafficking in innate phagocytes such as macrophages and professional antigen presenting dendritic cells (DCs). Although previous studies demonstrated the involvement of PI3K isoforms in innate and adaptive immune cell types, the role of PI3Ks with respect to DC biology has been enigmatic. Thus, this review, based on studies involving PI3K isoforms, highlight how the different PI3Ks isoforms could regulate DC functions such as antigen processing and presentation including PRR responses.
Collapse
Affiliation(s)
- Ezra Aksoy
- Centre for Biochemical Pharmacology, William Harvey Research Institute, Bart's and the London School of Medicine Queen Mary University of London, London, United Kingdom
| | - Loredana Saveanu
- Institut National de la Santé et de la Recherche Médicale, Unité UMR 1149, Centre de Recherche sur l'Inflammation, Paris, France
- Université Paris Diderot, Faculté de Médecine Xavier Bichat, Paris, France
| | - Bénédicte Manoury
- Institut Necker Enfants Malades, Institut National de la Santé et de la Recherche Médicale, Unité 1151, Paris, France
- Centre National de la Recherche Scientifique, Unité 8253, Paris, France
- Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine Paris Descartes, Paris, France
| |
Collapse
|